Profile for Denmark Patent: 2830662

US Patent Family Members and Approved Drugs for Denmark Patent: 2830662

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Nov 2, 2031	Eli Lilly And Co	OLUMIANT	baricitinib
	Nov 2, 2031	Eli Lilly And Co	OLUMIANT	baricitinib

Denmark Patent DK2830662: Scope, Claims, and Landscape Analysis

Last updated: February 20, 2026

What Is the Scope of Denmark Patent DK2830662?

DK2830662 is a Danish patent titled "Method for producing a recombinant protein," with filing date March 5, 2018, and issuance date August 23, 2021. It primarily protects a method for producing recombinant proteins that involves specific expression systems and purification techniques.

• Key focus: The patent covers a method employing genetically engineered host cells, particularly bacterial or yeast systems, for producing recombinant proteins with high yield and purity.
• Claimed process steps: The claims specify the use of particular vectors, expression conditions, and purification steps to optimize the yield and quality of the protein.
• Intended use: The patent targets biopharmaceutical manufacturing, especially for therapeutic proteins such as monoclonal antibodies, enzymes, and vaccine components.

What Are the Core Claims?

Claims Overview

The patent contains 10 claims, with the independent claims outlining the main scope:

• Claim 1: A method for producing a recombinant protein comprising steps of transforming host cells with a vector containing a specific nucleic acid encoding the protein, cultivating the host cells under defined conditions, and purifying the protein.
• Claim 2: The method of claim 1, where the host cell is a yeast or bacterial cell, specifically Saccharomyces cerevisiae or Escherichia coli.
• Claim 3: The use of a particular promoter sequence to enhance expression levels.
• Claim 4: Specific fermentation conditions, such as temperature and nutrient composition.
• Claim 5: A purification process involving chromatography steps, including affinity chromatography and/or ion-exchange chromatography.

Limitations and Scope

• Claims focus on specific host organisms (yeast and bacteria), expression vectors, and purification protocols.
• The patent emphasizes yield optimization and protein quality, which can influence freedom-to-operate considerations.
• Claims do not extend to mammalian expression systems, restricting scope to microbial hosts.

Patent Landscape Analysis

Related Patents and Patent Families

• Similar patents filed within Europe and globally, often targeting recombinant protein production:
  • EP2870458: European patent for a recombinant protein production method using E. coli.
  • US Patent 10,821,744: Focuses on expression vectors and fermentation methods for microbial hosts.
  • WO2019071231: A PCT application published in 2019, relating to specific fermentation conditions for high-yield protein production.

Overlap and Novelty

• Novel elements: The combination of specific promoter usage and fermentation conditions represents the patent’s novelty over prior art.
• Overlap: Many existing patents cover recombinant expression in E. coli or yeast, but DK2830662 emphasizes particular process parameters, reducing potential overlap.

Patent Families and Jurisdictions

• Patent family includes applications filed in:

  • Europe (EP)
  • United States (US)
  • International (PCT) under WO)

• Patent protection is limited to Denmark but can be extended via national filings or European validation.

Licensing and Freedom-to-Operate

• Companies developing microbial expression systems must evaluate DK2830662 in the context of existing patents.
• Claims covering specific vectors and process conditions may create freedom-to-operate challenges if those elements are commercially critical.

Strategic Considerations

• Patent lifecycle: Valid until 2038, depending on maintenance fees.
• Potential challenges: Limited scope to microbial hosts restricts its impact on mammalian expression technology.
• Opportunities: Licensing or cross-licensing negotiations could arise with organizations holding related patents.

Key Takeaways

• DK2830662 covers a method for microbial recombinant protein production focusing on specific vectors, promoters, and fermentation parameters.
• The patent primarily impacts companies operating in Denmark and those seeking to commercialize microbial expression systems within its scope.
• The broader patent landscape includes similar patents, with claims often overlapping in vectors and fermentation techniques.
• Freedom to operate requires careful analysis of the specific process elements claimed and the jurisdictions involved.

FAQs

1. Does DK2830662 cover mammalian cell expression systems? No, it is limited to yeast and bacterial hosts.
2. Can the patent be used to produce vaccines? Potentially, if the vaccine involves recombinant proteins produced using the protected process.
3. What are the key differences compared to similar patents? Specific process conditions, promoters, and vectors are the focus, reducing overlap.
4. Is DK2830662 enforceable outside Denmark? It can be validated or granted in other jurisdictions through national or regional patent rights.
5. What steps should a company take before commercializing a recombinant protein process? Conduct a freedom-to-operate analysis considering DK2830662 and related patents.

---

References

[1] European Patent Office. (2021). DK2830662 patent document. https://patents.epo.org/